VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+46.01%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$648M
AUM Growth
+$648M
(+28%)
Cap. Flow
+$30M
Cap. Flow
% of AUM
4.63%
Top 10 Holdings %
Top 10 Hldgs %
69.93%
Holding
36
New
9
Increased
7
Reduced
3
Closed
5
Top Buys
| 1 |
Pliant Therapeutics
PLRX
|
$22.6M |
| 2 |
Milestone Pharmaceuticals
MIST
|
$22.3M |
| 3 |
Terns Pharmaceuticals
TERN
|
$21.8M |
| 4 |
Gossamer Bio
GOSS
|
$20.9M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$20.1M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
$41.5M |
| 2 |
Relmada Therapeutics
RLMD
|
$27.8M |
| 3 |
Celldex Therapeutics
CLDX
|
$22.2M |
| 4 |
VistaGen Therapeutics
VTGN
|
$18.2M |
| 5 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$14.5M |
Sector Composition
| 1 | Healthcare | 96.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCDA
1
DELISTED
Tricida, Inc. Common Stock
TCDA
| $94.8M | 14.63% | 9,050,064 +1,917,985 | +27% | +$20.1M |
|
2
Aclaris Therapeutics
ACRS
$209M
| $71.8M | 11.08% | 4,563,962 | – | – |
|
3
Cogent Biosciences
COGT
$1.69B
| $60.2M | 9.3% | 4,038,117 | – | – |
|
|
4
Relmada Therapeutics
RLMD
$37.2M
| $56.2M | 8.67% | 1,518,056 -752,016 | -33% | -$27.8M |
|
5
Viridian Therapeutics
VRDN
$1.5B
| $43.7M | 6.74% | 2,130,308 +277,389 | +15% | +$5.69M |
|
6
GH Research
GHRS
$837M
| $38.7M | 5.98% | 3,333,154 +147,581 | +5% | +$1.71M |
|
|
7
Pliant Therapeutics
PLRX
$101M
| $22.6M | 3.48% | +1,080,000 | New | +$22.6M |
|
|
8
Milestone Pharmaceuticals
MIST
$156M
| $22.3M | 3.44% | +2,425,737 | New | +$22.3M |
|
|
9
Terns Pharmaceuticals
TERN
$609M
| $21.8M | 3.37% | +3,707,891 | New | +$21.8M |
|
|
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $21M | 3.24% | 3,156,803 | – | – |
|
|
11
Gossamer Bio
GOSS
$562M
| $20.9M | 3.23% | +1,747,000 | New | +$20.9M |
|
12
Annexon
ANNX
$226M
| $19.9M | 3.07% | 3,220,050 +1,291,573 | +67% | +$7.98M |
|
13
Instil Bio
TIL
$182M
| $19.9M | 3.07% | 4,105,779 -1,891,878 | -32% | -$9.16M |
|
|
AKUS
14
DELISTED
Akouos, Inc. Common Stock
AKUS
| $18.9M | 2.92% | 2,800,566 +133,447 | +5% | +$902K |
|
|
DICE
15
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $15.5M | 2.39% | +764,979 | New | +$15.5M |
|
|
JBIO
16
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $13.8M | 2.13% | 833,927 +243,519 | +41% | +$4.04M |
|
|
LIAN
17
DELISTED
LianBio American Depositary Shares
LIAN
| $10.8M | 1.66% | 5,378,341 | – | – |
|
18
Fulcrum Therapeutics
FULC
$351M
| $9.71M | 1.5% | +1,200,000 | New | +$9.71M |
|
|
INZY
19
DELISTED
Inozyme Pharma
INZY
| $7.26M | 1.12% | 2,709,987 | – | – |
|
20
Ventyx Biosciences
VTYX
$171M
| $7.26M | 1.12% | +207,925 | New | +$7.26M |
|
|
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $7.18M | 1.11% | +121,663 | New | +$7.18M |
|
22
Savara
SVRA
$567M
| $7.06M | 1.09% | 4,555,038 +437,508 | +11% | +$678K |
|
|
PRVB
23
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $5.03M | 0.78% | 1,118,653 | – | – |
|
24
Altimmune
ALT
$338M
| $4.72M | 0.73% | 369,306 | – | – |
|
25
Trevi Therapeutics
TRVI
$883M
| $4.7M | 0.72% | 3,050,022 | – | – |
|